Corrigendum: Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer (Annals of Oncology (2018) 29 (i28–i37) (DOI: 10.1093/annonc/mdx705)

C. Ricordel; L. Friboulet; F. Facchinetti; J. C. Soria

doi:10.1093/annonc/mdy222

Corrigendum: Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer (Annals of Oncology (2018) 29 (i28–i37) (DOI: 10.1093/annonc/mdx705)

C. Ricordel, L. Friboulet, F. Facchinetti, J. C. Soria

Research output: Contribution to journal › Comment/debate

15 Citations (Scopus)

Abstract

In the original article, the sentence "Occurrence of grade 3 and 4 interstitial lung disease has been reported in 38% (13/34) of patients exposed to the combination of osimertinib plus durvalumab [73], . . ." Has been corrected to "Occurrence of interstitial lung disease has been reported in 38% (13/34) of patients exposed to the combination of osimertinib plus durvalumab, of which five were of grade 3 and 4 [73], . . .".

Original language	English
Article number	mdy222
Pages (from-to)	858
Number of pages	1
Journal	Annals of Oncology
Volume	30
Issue number	5
DOIs	https://doi.org/10.1093/annonc/mdy222
Publication status	Published - 1 May 2019

Access to Document

10.1093/annonc/mdy222

Cite this

@article{470f23f9f93c44e3a258939b68bf3497,

title = "Corrigendum: Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer (Annals of Oncology (2018) 29 (i28–i37) (DOI: 10.1093/annonc/mdx705)",

abstract = "In the original article, the sentence {"}Occurrence of grade 3 and 4 interstitial lung disease has been reported in 38% (13/34) of patients exposed to the combination of osimertinib plus durvalumab [73], . . .{"} Has been corrected to {"}Occurrence of interstitial lung disease has been reported in 38% (13/34) of patients exposed to the combination of osimertinib plus durvalumab, of which five were of grade 3 and 4 [73], . . .{"}.",

author = "C. Ricordel and L. Friboulet and F. Facchinetti and Soria, {J. C.}",

year = "2019",

month = may,

day = "1",

doi = "10.1093/annonc/mdy222",

language = "English",

volume = "30",

pages = "858",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "5",

}

Corrigendum: Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer (Annals of Oncology (2018) 29 (i28–i37) (DOI: 10.1093/annonc/mdx705). / Ricordel, C.; Friboulet, L.; Facchinetti, F. et al.
In: Annals of Oncology, Vol. 30, No. 5, mdy222, 01.05.2019, p. 858.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum

T2 - Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer (Annals of Oncology (2018) 29 (i28–i37) (DOI: 10.1093/annonc/mdx705)

AU - Ricordel, C.

AU - Friboulet, L.

AU - Facchinetti, F.

AU - Soria, J. C.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - In the original article, the sentence "Occurrence of grade 3 and 4 interstitial lung disease has been reported in 38% (13/34) of patients exposed to the combination of osimertinib plus durvalumab [73], . . ." Has been corrected to "Occurrence of interstitial lung disease has been reported in 38% (13/34) of patients exposed to the combination of osimertinib plus durvalumab, of which five were of grade 3 and 4 [73], . . .".

AB - In the original article, the sentence "Occurrence of grade 3 and 4 interstitial lung disease has been reported in 38% (13/34) of patients exposed to the combination of osimertinib plus durvalumab [73], . . ." Has been corrected to "Occurrence of interstitial lung disease has been reported in 38% (13/34) of patients exposed to the combination of osimertinib plus durvalumab, of which five were of grade 3 and 4 [73], . . .".

UR - http://www.scopus.com/inward/record.url?scp=85057015213&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy222

DO - 10.1093/annonc/mdy222

M3 - Comment/debate

C2 - 29982319

AN - SCOPUS:85057015213

SN - 0923-7534

VL - 30

SP - 858

JO - Annals of Oncology

JF - Annals of Oncology

IS - 5

M1 - mdy222

ER -

Corrigendum: Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer (Annals of Oncology (2018) 29 (i28–i37) (DOI: 10.1093/annonc/mdx705)

Abstract

Access to Document

Other files and links

Cite this